These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6424970)

  • 1. Testosterone, 17 Ks, 17 beta E2 FSH-LH variations and hirsutism modifications during spironolactone therapy.
    Spandri P; Gangemi M; Nardelli GB; Meneghetti G; Grandesso R; De Salvia D; Ambrosio GB; Predebon O
    Clin Exp Obstet Gynecol; 1984; 11(1-2):49-54. PubMed ID: 6424970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hirsutism--a low dose spironolactone therapy.
    Vĕtr M
    Acta Univ Palacki Olomuc Fac Med; 1989; 122():239-45. PubMed ID: 2530821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal changes and hair growth during treatment of hirsutism with cimetidine.
    Grandesso R; Spandri P; Gangemi M; Nardelli GB; Ambrosio GB; Conte G; De Salvia D; Meneghetti G
    Clin Exp Obstet Gynecol; 1984; 11(3):105-9. PubMed ID: 6426822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone as a single agent for long-term therapy of hirsute patients.
    Spritzer PM; Lisboa KO; Mattiello S; Lhullier F
    Clin Endocrinol (Oxf); 2000 May; 52(5):587-94. PubMed ID: 10792338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone in the treatment of hirsutism.
    Köksal A; Pabuçcu R; Akyürek C
    Arch Gynecol; 1987; 240(2):95-100. PubMed ID: 3105474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
    Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
    Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism.
    De Leo V; Fulghesu AM; la Marca A; Morgante G; Pasqui L; Talluri B; Torricelli M; Caruso A
    Gynecol Endocrinol; 2000 Dec; 14(6):411-6. PubMed ID: 11228061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of spironolactone on testosterone and LHRH responsiveness in women with polycystic ovarian disease.
    Evron S; Yosef SM; Schenker JG; Diamant YZ
    Isr J Med Sci; 1984 Jul; 20(7):630-3. PubMed ID: 6432730
    [No Abstract]   [Full Text] [Related]  

  • 9. Factors affecting the degree of hirsutism in patients with polycystic ovary syndrome.
    Guzel AI; Kuyumcuoğlu U; Celik Y
    Arch Gynecol Obstet; 2012 Mar; 285(3):767-70. PubMed ID: 21909749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dose spironolactone in the treatment of female hyperandrogenemia and hirsutism.
    Vĕtr M; Sobek A
    Acta Univ Palacki Olomuc Fac Med; 1993; 135():55-7. PubMed ID: 7976677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of low-dose GnRH analogue (Buserelin) in the treatment of hirsutism.
    Bertoli A; Fusco A; Magnani A; Marini MA; Di Daniele N; Gatti S; Lauro R
    Exp Clin Endocrinol Diabetes; 1995; 103(1):15-20. PubMed ID: 7621099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
    Rittmaster RS; Thompson DL
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
    Falsetti L; Galbignani E
    Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Spironolactone in idiopathic hirsutism, clinical and biological evaluation of treatment].
    Abramovici Y; Guillet F; Matte R; Chaieb L; Belanger R
    Ann Endocrinol (Paris); 1983; 44(6):393-6. PubMed ID: 6430208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extremely high levels of estradiol and testosterone in a case of polycystic ovarian syndrome. Hormone and clinical similarities with the phenotype of the alpha estrogen receptor null mice.
    Bartolone L; Smedile G; Arcoraci V; Trimarchi F; Benvenga S
    J Endocrinol Invest; 2000; 23(7):467-72. PubMed ID: 11005272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome.
    Evans DJ; Burke CW
    J R Soc Med; 1986 Aug; 79(8):451-3. PubMed ID: 3761287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of estrogen administration on androgen production and plasma luteinizing hormone in hirsute women.
    Kirschner MA; Bardin CW; Hembree WC; Ross GT
    J Clin Endocrinol Metab; 1970 Jun; 30(6):727-32. PubMed ID: 5444560
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential suppression of testosterone and estradiol in hirsute women with the superactive gonadotropin-releasing hormone agonist leuprolide.
    Rittmaster RS
    J Clin Endocrinol Metab; 1988 Oct; 67(4):651-5. PubMed ID: 3138274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
    J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism.
    Sert M; Tetiker T; Kirim S
    Acta Med Okayama; 2003 Apr; 57(2):73-6. PubMed ID: 12866746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.